Pacific Software, Inc.
PFSF
Other OTC0.03
USD
- -
- -
CIK
0001400732
ISIN
US69482P2056
CUSIP
69482P205
Return %
Stock
S&P500
1Y
275.00
26.53
3Y
-41.18
76.60
5Y
-98.94
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Izak On
- Full Time Employees
- 1
- Sector
- Consumer Cyclical
- Industry
- Restaurants
- Address
- 2 Bloor St East Toronto ON Canada M4W1A8
- IPO Date
- Mar 18, 2011
- CIK
- 0001400732
- Website
- pacificsoftwareinc.com
- Similar Companies
- Business
- Pacific Software, Inc. engages primarily in the development, acquisition, and commercialization of software and technology-driven products with recent strategic expansions into cosmeceuticals and neuro-medicine. The company offers full-stack web development; mobile application development including native iOS/Android and cross-platform React Native apps; and cloud infrastructure solutions encompassing scalable cloud services, migration, and optimization on AWS, Azure, and GCP. It also provides technology platforms and proprietary software assets in the dermatological and neuromedicine sectors such as the patented Dermatrix cosmeceutical technology for skin care and a portfolio of neuro-medicine assets focused on small molecule and psychoactive compounds for neurological and psychiatric conditions. Founded in 2005 and headquartered in Dana Point, California, Pacific Software serves markets across North America with a diversified client base in agriculture, fertilizer, chemicals, cosmetics, electronics, and equipment industries. The company acquired certain business assets of Dreamaderm Inc. in early 2024, gaining exclusive rights to its Dermatrix cosmeceutical technology, positioning itself in the cosmetics and skin care sector. In August 2025, Pacific Software completed the acquisition of 10763942 Canada Inc. and the PurMinds asset portfolio from PurMinds NeuroPharma Inc., advancing its clinical-stage neuro-medicine pipeline. This acquisition elevated the company's presence in precision neuromedicine with 4P healthcare (predictive, preventive, personalized, participatory) platforms integrating diagnostic and therapeutic technologies. In late 2025, Pacific Software announced an exclusive partnership with SpectroChip Global to develop and commercialize diagnostic platforms that complement its neuro-medicine clinical programs by enhancing patient stratification and health data analytics. The company is in the process of potentially rebranding to PurMinds Enterprises, reflecting its broadened focus on neuropharmaceuticals and diagnostics. These recent changes highlight a strategic diversification beyond traditional software services toward health technology innovation and asset commercialization, aiming at new revenue streams in emerging biotech and cosmeceutical markets. Pacific Software, Inc. continuously integrates advanced software technologies with life sciences assets, combining cross-sector expertise to develop novel market opportunities and technology-driven healthcare solutions. Its operations span multiple segments including application software development, dermatological innovation, and clinical neuro-medicine, targeting consumer health, pharmaceuticals, and enterprise technology customers. The company maintains a strategic orientation to leverage recent acquisitions and partnerships for growth and innovation.
Pacific Software, Inc. Announces Completion of Change of Control with PurMinds Holdings Inc.; Confirms Occupancy of a GMP Production Facility; and OTCQX Uplisting Strategy
Pacific Software Inc Announces Exclusive Partnership with SpectroChip Global
Professor Dr. Robert Schiestl Ph. D. Joins Pacific Software Inc. as Chief Science Advisor (CSA)
Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.